<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344522</url>
  </required_header>
  <id_info>
    <org_study_id>DMEK ACIOL</org_study_id>
    <nct_id>NCT04344522</nct_id>
  </id_info>
  <brief_title>Descemet Membrane Endothelial Keratoplasty Combined With Intraocular Lens Exchange: Sequential Versus Combined Surgery</brief_title>
  <official_title>Descemet Membrane Endothelial Keratoplasty Combined With Intraocular Lens Exchange: Sequential Versus Combined Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical treatment of corneal endothelial decompensation in the presence of an anterior
      chamber intraocular lens (AC IOL) is technically challenging. The ultimate management is to
      perform Descemet membrane endothelial keratoplasty (DMEK). However , unfolding the DMEK graft
      in the presence of an AC IOL can be difficult and injurious to the graft so the investigators
      recommend exchanging the AC IOL with a posterior chamber IOL first. In this study , the
      investigators aim to compare the outcome and complications of performing DMEK and IOL
      exchange as combined one stage surgery versus .sequential 2 stage procedure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pseudophakic Bullous keratopathy is the second leading indication for endothelial
      keratoplasty. One of the main controversies in the management of PBK in the presence of an AC
      IOl is whether to retain the IOL or perform an IOL exchange with a PC IOL. The investigators
      believe that retention of an AC IOL can be hazardous to the DMEK graft due to reduced depth
      of the anterior chamber and traumatic touch between the graft and the IOL during graft
      unfolding and even postoperatively. On the other hand , performing an IOL exchange is
      relatively time consuming and requires excess manipulation of the iris tissue with the risk
      of intraoperative hyphema and postoperative inflammation which can affect the endothelial
      graft survival and cell count.

      Aim of the study : to compare the outcome and complications between performing intraocular
      lens (IOL) exchange and Descemet membrane endothelial keratoplasty (DMEK) as single stage
      versus two stage procedure in the management of pseudophakic bullous keratopathy associated
      with anterior chamber IOL.

      Methods :

      The study will be a prospective randomized controlled trial. Eligible subjects with
      pseudophakic bullous keratopathy and AC IOL will be assigned into two groups each comprising
      10 eyes. One group will undergo AC IOL exchange with posterior chamber (PC) IOL ( Poly methyl
      methacrylate (PMMA) lens or iris claw lens if there is no adequate capsular support) combined
      with DMEK in the same setting. The other group will undergo 2 stage procedure ; first one is
      IOL exchange , iridoplasty (if required) and inferior peripheral iridectomy and the second
      stage is DMEK one month later.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative endothelial cell loss in percentage</measure>
    <time_frame>3 months</time_frame>
    <description>The postoperative endothelial cell count will be determined in cell/mm2 using the Konan Cellchek specular microscope (Konan Medical , Irvine, California , USA) at 3 months and compared to the preoperative endothelial cell count of the donor graft to calculate the percentage of endothelial cell loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best spectacle corrected visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>best spectacle corrected visual acuity using the decimal system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative hyphema and and intraocular pressure spikes</measure>
    <time_frame>1month postoperatively</time_frame>
    <description>Any postoperative hyphema and anterior chamber inflammatory reactions will determined by slit lamp examination:
Hyphema if found will be graded into :
Microscopic hyphema : circulating red blood cells in the AC
Grade I : less than one third the AC
Grade II: one third to one half the AC
Grade III: more than one half the AC but not total
Grade IV : total hyphema. and intraocular pressure spikes will detected using the Goldmann applanation tonometer to measure the intraocular pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative AC inflammatory reactions</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>postoperative AC inflammatory reactions including cell and flare will be determined by slit lamp examination under high magnification:
AC cells will be graded according to the Standardization of Uveitis Nomenclature (SUN) group grading system as following :
Grade 0 : 5 or less cells in 1*1mm slit beam Grade 1 : 6- 15 cells in 1*1mm slit beam Grade II : 16-25 cells in 1*1mm slit beam Grade III : 26-50 cells in 1*1mm slit beam grade IV : more than 50 cells in 1*1mm slit beam .
AC flare will be graded according to the SUN grading system :
Grade 0 : none Grade I : faint Grade II : moderate ( iris and lens details still seen ) Grade III : Marked ( iris and lens details hazy) Grade IV : intense ( fixed and plastic aqueous ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative intraocular pressure spikes</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>postoperative intracular pressure will be measured by Goldmann Applanation Tonometer in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Keratometric values</measure>
    <time_frame>3 months</time_frame>
    <description>Keratometric values will be determined in Diopters using Autorefractometer/Keratometer , the difference between the steep and flat keratometric values will determine the corneal astigamtism in diopters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central corneal thickness</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>central corneal thickness will be determined in micrometer using the Konan Cellchek specular microscope (Konan Medical , Irvine, California , USA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft detachment</measure>
    <time_frame>1 week postoperatively</time_frame>
    <description>The occurrence of postoperative graft detachment will be determined by slit lamp examination . The incidence of graft detachment will be determined in each group .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spherical equivalent</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>spherical equivalent will be determined using the autorefractometer in diopters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pseudophakic Bullous Keratopathy</condition>
  <condition>Anterior Chamber Intraocular Lens</condition>
  <arm_group>
    <arm_group_label>sequential 2 stage procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combined single stage procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, both IOL exchange and DMEK will be performed in the same setting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Descemet membrane endothelial keratoplasty DMEK</intervention_name>
    <description>DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.</description>
    <arm_group_label>combined single stage procedure</arm_group_label>
    <arm_group_label>sequential 2 stage procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IOL exchange</intervention_name>
    <description>IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.</description>
    <arm_group_label>combined single stage procedure</arm_group_label>
    <arm_group_label>sequential 2 stage procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>iridoplasty</intervention_name>
    <description>iridoplasty : repairing any iris defect by using 10/0 prolene.</description>
    <arm_group_label>combined single stage procedure</arm_group_label>
    <arm_group_label>sequential 2 stage procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inferior peripheral iridectomy</intervention_name>
    <description>Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .</description>
    <arm_group_label>combined single stage procedure</arm_group_label>
    <arm_group_label>sequential 2 stage procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients having pseudophakic bullous keratopathy associated with an anterior chamber
             intraocular lens.

          2. Age above 18 years old.

        Exclusion Criteria:

          1. Patients with corneal stromal scarring .

          2. Patients who had prior glaucoma drainage devices implantation. 3 Patient with
             non-repairable loss in the iris tissue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed M Kolaib, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed B Goweida, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alexandria Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed M Kolaib, MBBCh</last_name>
    <phone>00201283674800</phone>
    <email>mohamedkolaib@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed B Goweida, MD</last_name>
    <phone>00201011755557</phone>
    <email>mbahgat@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohamed M Kolaib, MBBCh</last_name>
      <phone>00201283674800</phone>
      <email>mohamedkolaib@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed B Goweida, MD</last_name>
      <phone>00201011755557</phone>
      <email>mbahgat@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Melles GR, Ong TS, Ververs B, van der Wees J. Preliminary clinical results of Descemet membrane endothelial keratoplasty. Am J Ophthalmol. 2008 Feb;145(2):222-227. Epub 2007 Dec 3.</citation>
    <PMID>18061137</PMID>
  </reference>
  <reference>
    <citation>Ham L, Dapena I, van Luijk C, van der Wees J, Melles GR. Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy: review of the first 50 consecutive cases. Eye (Lond). 2009 Oct;23(10):1990-8. doi: 10.1038/eye.2008.393. Epub 2009 Jan 30.</citation>
    <PMID>19182768</PMID>
  </reference>
  <reference>
    <citation>Dapena I, Ham L, Melles GR. Endothelial keratoplasty: DSEK/DSAEK or DMEK--the thinner the better? Curr Opin Ophthalmol. 2009 Jul;20(4):299-307. doi: 10.1097/ICU.0b013e32832b8d18. Review.</citation>
    <PMID>19417653</PMID>
  </reference>
  <reference>
    <citation>Woo JH, Ang M, Htoon HM, Tan D. Descemet Membrane Endothelial Keratoplasty Versus Descemet Stripping Automated Endothelial Keratoplasty and Penetrating Keratoplasty. Am J Ophthalmol. 2019 Nov;207:288-303. doi: 10.1016/j.ajo.2019.06.012. Epub 2019 Jun 19.</citation>
    <PMID>31228467</PMID>
  </reference>
  <reference>
    <citation>Pricopie S, Istrate S, Voinea L, Leasu C, Paun V, Radu C. Pseudophakic bullous keratopathy. Rom J Ophthalmol. 2017 Apr-Jun;61(2):90-94. Review.</citation>
    <PMID>29450379</PMID>
  </reference>
  <reference>
    <citation>Ravalico G, Botteri E, Baccara F. Long-term endothelial changes after implantation of anterior chamber intraocular lenses in cataract surgery. J Cataract Refract Surg. 2003 Oct;29(10):1918-23.</citation>
    <PMID>14604711</PMID>
  </reference>
  <reference>
    <citation>Liarakos VS, Ham L, Dapena I, Tong CM, Quilendrino R, Yeh RY, Melles GR. Endothelial keratoplasty for bullous keratopathy in eyes with an anterior chamber intraocular lens. J Cataract Refract Surg. 2013 Dec;39(12):1835-45. doi: 10.1016/j.jcrs.2013.05.045.</citation>
    <PMID>24286840</PMID>
  </reference>
  <reference>
    <citation>Gupta PK, Bordelon A, Vroman DT, Afshari NA, Kim T. Early outcomes of descemet stripping automated endothelial keratoplasty in pseudophakic eyes with anterior chamber intraocular lenses. Am J Ophthalmol. 2011 Jan;151(1):24-28.e1. doi: 10.1016/j.ajo.2010.07.003. Epub 2010 Oct 20.</citation>
    <PMID>20970110</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Mohamed Kolaib</investigator_full_name>
    <investigator_title>Ophthalmology resident</investigator_title>
  </responsible_party>
  <keyword>Descemet membrane endothelial keratoplasty DMEK</keyword>
  <keyword>Anterior chamber intraocular lens AC IOL</keyword>
  <keyword>pseudophakic bullous keratopathy PBK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

